Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF act mut |
| Therapy | Sorafenib |
| Indication/Tumor Type | melanoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF act mut | melanoma | no benefit | Sorafenib | Phase II | Actionable | In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203). | 22394203 16880785 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22394203) | Sorafenib in melanoma. | Full reference... |
| (16880785) | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. | Full reference... |